drugset / Trial / NCT00285012

Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).

NCT00285012

Phase 3 Completed 504 enrolled Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.

Timeline

Start
2006-05
Primary completion
2008-07
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Varenicline Small molecule 1 mg Oral

Indications

No indication recorded.